丙型肝炎病毒感染疾病负担管理策略 - 第3卷

Strategies to manage hepatitis C virus infection disease burden - volume 3.

作者信息

Alfaleh F Z, Nugrahini N, Matičič M, Tolmane I, Alzaabi M, Hajarizadeh B, Valantinas J, Kim D Y, Hunyady B, Abaalkhail F, Abbas Z, Abdou A, Abourached A, Al Braiki F, Al Hosani F, Al Jaberi K, Al Khatry M, Al Mulla M A, Al Quraishi H, Al Rifai A, Al Serkal Y, Alam A, Alashgar H I, Alavian S M, Alawadhi S, Al-Dabal L, Aldins P, Alghamdi A S, Al-Hakeem R, Aljumah A A, Almessabi A, Alqutub A N, Alswat K A, Altraif I, Andrea N, Assiri A M, Babatin M A, Baqir A, Barakat M T, Bergmann O M, Bizri A R, Chaudhry A, Choi M S, Diab T, Djauzi S, El Hassan E S, El Khoury S, Estes C, Fakhry S, Farooqi J I, Fridjonsdottir H, Gani R A, Ghafoor Khan A, Gheorghe L, Goldis A, Gottfredsson M, Gregorcic S, Gunter J, Hamid S, Han K H, Hasan I, Hashim A, Horvath G, Husni R, Jafri W, Jeruma A, Jonasson J G, Karlsdottir B, Kim Y S, Koutoubi Z, Lesmana L A, Liakina V, Lim Y S, Löve A, Maimets M, Makara M, Malekzadeh R, Memon M S, Merat S, Mokhbat J E, Mourad F H, Muljono D H, Nawaz A, Olafsson S, Priohutomo S, Qureshi H, Rassam P, Razavi H, Razavi-Shearer D, Razavi-Shearer K, Rozentale B, Sadik M, Saeed K, Salamat A, Salupere R, Sanai F M, Sanityoso Sulaiman A, Sayegh R A, Schmelzer J D, Sharara A I, Sibley A, Siddiq M, Siddiqui A M, Sigmundsdottir G, Sigurdardottir B, Speiciene D, Sulaiman A, Sultan M A, Taha M, Tanaka J, Tarifi H, Tayyab G, Ud Din M, Umar M, Videčnik-Zorman J, Yaghi C, Yunihastuti E, Yusuf M A, Zuberi B F, Blach S

机构信息

Liver Disease Research Center, King Saud University, Riyadh, Saudi Arabia.

Sub-Directorate for Gastrointestinal Infection, Diarrheal Diseases, and Hepatitis, Directorate of Direct Transmitted Disease Control, Disease Control & Environmental Health, Ministry of Health, Jakarta, Indonesia.

出版信息

J Viral Hepat. 2015 Dec;22 Suppl 4:42-65. doi: 10.1111/jvh.12474.

DOI:10.1111/jvh.12474

PMID:26513447

Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).

摘要

对欧洲、中东和亚洲的15个国家进行了至2030年的丙型肝炎病毒（HCV）疫情预测，并考虑了两种情景的相对影响：在保持每年接受治疗的患者数量不变的情况下提高治疗效果，以及提高治疗效果并增加每年接受治疗的患者数量。提高诊断和治疗水平，同时提高治疗效果，对于大幅减轻疾病负担至关重要。在所研究的大多数国家，15年内将HCV总感染率降低90%是可行的，但这需要协调努力，引入减少伤害计划以减少新感染，进行筛查以识别已感染者，并采用高治愈率疗法进行治疗。这表明，在许多国家，提高筛查和治疗能力将至关重要。出生队列筛查是优化资源的有用工具。在欧洲国家，大多数患者出生于1940年至1985年之间。在中东和亚洲观察到更广泛的出生队列（1925年至1995年之间）。